A history of underperformance
04/08/2011 - Prolor president Shai Novik told "Globes" that the trial's results exceeded expectations, and could enable the company to move directly to a Phase III clinical trial. The Phase III trial will include 150-200 adults with growth hormone deficiency and take six months to prove the treatment's efficacy and twelve months to confirm its safety. "We're working hard to submit the trial application in the first quarter of 2012," he said.
Sentiment: Hold